Mineralys Therapeutics
MLYS
68 hedge funds and large institutions have $429M invested in Mineralys Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 9 reducing their positions, and 10 closing their positions.
244% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 9
11% more capital invested
Capital invested by funds: $385M → $429M (+$43.8M)
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 67 → 68 (+1)
1.4% more ownership
Funds ownership: 60.24% → 61.64% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.48M |
| 3 |
BlackRock
New York
|
+$2.01M |
| 4 |
DM
Deerfield Management
New York
|
+$1.61M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.43M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.99M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.94M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.8M |
MLYS Hedge Fund Activity: Q2 2023 in Review
68 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q2 2023, worth a combined $429M — up 11% from $385M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MLYS positions and 10 closed out — a net gain of 1 holder — while 31 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $10.9M. The largest seller was Avidity Partners Management, cutting an estimated $7.43M.
- 68 institutional investors held Mineralys Therapeutics (MLYS) as of Q2 2023, up from 67 in Q1 2023.
- Funds reported $429M of Mineralys Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
- 11 funds opened new Mineralys Therapeutics positions in Q2 2023 and 10 closed out, a net change of +1 holder.
- The largest Mineralys Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $10.9M added.
- The largest Mineralys Therapeutics seller in Q2 2023 was Avidity Partners Management, an estimated $7.43M sold.
Based on aggregated 13F filings for Q2 2023.